May 20, 2013 | Singapore's A*STAR and Swiss group Cytos Biotechnology have launched a Phase 1 clinical trial for an H1N1 flu vaccine, making use of Cytos’ virus-like particle (VLP) technology. If the trial is successful, the model may be quickly applied to other flu strains in the future. MedicalXpress